INTS
Intensity Therapeutics, Inc. Common stockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$13.34M
P/E Ratio
—
EPS
$-8.56
Beta
4.23
52W High
$50.00
52W Low
$4.63
50-Day MA
$7.43
200-Day MA
$8.41
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Intensity Therapeutics, Inc. Common stock
Intensity Therapeutics, Inc. is a forward-thinking biotechnology company focused on revolutionizing cancer treatment through its innovative drug delivery systems. By enhancing the efficacy of immuno-oncology therapies while minimizing systemic side effects, Intensity Therapeutics addresses critical unmet needs in the oncology landscape. With a robust foundation in cutting-edge research and a commitment to improving patient outcomes, the company is well-positioned to lead advancements in targeted therapies that effectively harness and amplify the body's immune response against cancer.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | -156.90% |
| Return on Assets | -79.20% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $4.70 |
| Price-to-Book | 1.21 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -4.72 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $2.54M |
| Float | $2.36M |
| % Insiders | 8.71% |
| % Institutions | 8.02% |
Analyst Ratings
Consensus ($48.67 target)
4
Buy1
HoldData last updated: 4/8/2026